

FDA clears Pathfast POC hs-cTnI test

April 12, 2024—[Polymedco](#) announced FDA 510(k) clearance of the Pathfast hs-cTnI-II, a high-sensitivity cardiac troponin assay for the diagnosis of myocardial infarction at the point of care. The test delivers results in 17 minutes on the Pathfast Biomarker analyzer using whole blood and plasma samples.